Physiologically based pharmacokinetic modelling to predict potential drug-drug interactions of dersimelagon (MT-7117).

ABSTRACT:

Aims

Dersimelagon is a novel, investigational, orally administered, selective agonist of the melanocortin-1 receptor that has demonstrated efficacy at increasing symptom-free light exposure and an acceptable safety profile in patients with protoporphyria. A phase 1 drug-drug interaction (DDI) study demonstrated that dersimelagon 300 mg has the potential for clinically relevant DDIs with drugs that are substrates for breast cancer resistance protein, such as atorvastatin and rosuvastatin. This study uses physiologically based pharmacokinetic (PBPK) modelling to further investigate the DDI effects at lower doses of dersimelagon with substrate drugs.

Methods

The data from in silico, in vitro and in vivo studies were used to construct a PBPK model for dersimelagon to assess the

SUBMITTER: Ogasawara A 

PROVIDER: S-EPMC11773107 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature